Study investigates management strategies for intermediate to high-risk prostate cancer
“We [at GenesisCare] would be really interested in looking at strategies to identify men that we think are aggressive but localized and offer them a chance to do a shorter course hormonal therapy, which is going to substantially improve quality of life without losing on the efficacy end,” says Bridget F. Koontz, MD.
In this video, Bridget F. Koontz, MD, discusses the background, findings, and takeaways of the study, “Five year results of short course complete androgen blockade with abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high risk prostate cancer,” presented recently at the 2021 American Society for Radiation Oncology Annual Meeting. She also reports updates in GenesisCare technologies related to prostate cancer. Koontz is a radiation oncologist, US chief medical officer, and deputy global chief medical officer for GenesisCare.
Olaparib monotherapy shows benefit in HRR+ biochemically recurrent prostate cancer
August 22nd 2024“This study is a breakthrough because it is the first trial to show that a non-hormonal drug can induce durable complete remissions in recurrent prostate cancer patients with BRCA2 mutations—one of the most aggressive subtypes of this disease,” says Emmanuel S. Antonarakis, MD.
